Updated on 13 May 2013
Singapore: ScinoPharm Taiwan and Taiwan-listed, China-based company, Coland, have formed a strategic alliance to develop a series of generic oncological drugs for China. Several Active Pharmaceutical Ingredients (APIs) have been selected from the list of ScinoPharm-developed APIs for development and future sales of injectable formulation products.
The cooperation utilizes ScinoPharm's process R&D and production advantages in the field of highly-potent oncological APIs and Coland's well-established marketing capabilities in China, to build an active presence within China's rapidly growing anti-cancer drug market.
Under the strategic alliance agreement, ScinoPharm will provide the APIs, a third party company will be commissioned to develop, formulate and register oncological pharmaceutical products, and then Coland and ScinoPharm will be co-responsible for the marketing and sales efforts in the Chinese market.
Dr Jo Shen, president and CEO, ScinoPharm, stated that, "ScinoPharm is elated to form a strategic alliance with Coland. Resources from both parties will be combined to establish a robust collaboration for assertive development of products for the local anti-cancer medication market in China. This cooperation also marks ScinoPharm's first move into Chinese market since launching our "Double A" strategy, combining unique APIs with Abbreviated New Drug Applications (ANDAs)."
Dr Shen also added, "High technical entry barrier APIs will be continually developed into formulations (ANDAs), providing the Chinese pharmaceutical market with a total solution for domestic demand. This strategy will extend our marketing networks to cover end users resulting in securing and expanding ScinoPharm's existing business while also enhancing the company's long-term competitive advantage and new opportunities for growth."